The role of osteopontin in kidney diseases

Inflammation Research

Volumn 68, Issue 2, 2019, Pages 93-102

  Kaleta, Beata ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Kidney; Kidney disease; Marker; Osteopontin

Indexed keywords

OSTEOPONTIN; BIOLOGICAL MARKER; SPP1 PROTEIN, HUMAN;

DIABETIC NEPHROPATHY; FOCAL GLOMERULOSCLEROSIS; GENETIC POLYMORPHISM; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY ALLOGRAFT REJECTION; KIDNEY CANCER; KIDNEY DISEASE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; ANIMAL; GENETICS; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BIOMARKERS; HUMANS; KIDNEY; KIDNEY DISEASES; OSTEOPONTIN;

EID: 85056691813     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-018-1200-5     Document Type: Review

References (117)

1. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun. 2001;280:460–5.
2. Pichler R, Giachelli CM, Lombardi D, Pippin J, Gordon K, Alpers CE, et al. Tubulointerstitial disease in glomerulonephritis. Potential role of osteopontin (uropontin). Am J Pathol. 1994;144:915–26.
3. Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci. 2008;103:4–13.
4. Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J. 1985;232:715–24.
5. Kruger TE, Miller AH, Godwin AK, Wang J. Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers. Crit Rev Oncol Hematol. 2014;89:330–41.
6. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993;7:1475–82.
7. Ross FP, Chappel J, Alvarez J, Sander D, Butler W, Farach-Carson M, et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem. 1993;268:9901–7.
8. Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 2000;19:615–22.
9. + T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol. 2008;181:7480–8.
10. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000;287:860–4.
11. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006;16:79–87.
12. Afify MF, Mohamed GB, El-Maboud MA, Abdel-Latif EA. Plasma concentration of osteopontin (OPN) in children with systemic lupus erythematosus: relationship with disease activity. Open Autoimmun J. 2009;1:59–63.
13. Cantor H. The role of Eta-1/osteopontin in the pathogenesis of immunological disorders. Ann N Y Acad Sci. 1995;760:143–50.
14. Carecchio M, Comi C. The role of osteopontin in neurodegenerative diseases. J Alzheimers Dis. 2011;25:179–85.
15. Frenzel DF, Weiss JM. Osteopontin and allergic disease: pathophysiology and implications for diagnostics and therapy. Expert Rev Clin Immunol. 2011;7:93–109.
16. Han S, Guthridge JM, Harley IT, Sestak AL, Kim-Howard X, Kaufman KM, et al. Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction. PLoS One. 2008;3:e0001757.
17. Konno S, Kurokawa M, Uede T. Role of osteopontin, a multifunctional protein, in allergy and asthma. Clin Exp Allergy. 2011;41:1360–6.
18. Mishima R, Takeshima F, Sawai T, Ohba K, Ohnita K, Isomoto H, et al. High plasma osteopontin levels in patients with inflammatory bowel disease. J Clin Gastroenterol. 2007;41:167–72.
19. Clemente N, Raineri D, Cappellano G, Boggio E, Favero F, Soluri M, et al. Osteopontin bridging innate and adaptive immunity in autoimmune diseases. J Immunol Res. 2016;2016:7675437.
20. Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol. 2004;26:179–84.
21. Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 2007;102:912–24.
22. Singh K, DeVouge MW, Mukherjee BB. Physiological properties and differential glycosylation of phosphorylated and nonphosphorylated forms of osteopontin secreted by normal rat kidney cells. J Biol Chem. 1990;265:18696–701.
23. Nagata T, Todescan R, Goldberg HA, Zhang Q, Sodek J. Sulphation of secreted phosphoprotein I (SPPI, osteopontin) is associated with mineralized tissue formation. Biochem Biophys Res Commun. 1989;165:234–40.
24. Sørensen ES, Højrup P, Petersen TE. Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci. 1995;4:2040–9.
25. Gimba ER, Tilli TM. Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett. 2013;331:11–7.
26. Inoue M, Shinohara ML. Intracellular osteopontin (iOPN) and immunity. Immunol Res. 2011;49:160–72.
27. Junaid A, Moon MC, Harding GE, Zahradka P. Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am J Physiol Cell Physiol. 2007;292:C919–26.
28. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sc USA. 1986;83:8819–23.
29. Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol. 1993;13:225–46.
30. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem. 1995;270:26232–8.
31. Green PM, Ludbrook SB, Miller DD, Horgan CM, Barry ST. Structural elements of the osteopontin SVVYGLR motif important for the interaction with alpha(4) integrins. FEBS Lett. 2001;503:75–9.
32. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996;271:509–12.
33. Hudkins KL, Giachelli CM, Cui Y, Couser WG, Johnson RJ, Alpers CE. Osteopontin expression in fetal and mature human kidney. J Am Soc Nephrol. 1999;10:444–57.
34. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. 2001;60:1645–57.
35. Rabb H, Barroso-Vicens E, Adams R, Pow-Sang J, Ramirez G. Alpha-V/beta-3 and alpha-V/beta-5 integrin distribution in neoplastic kidney. Am J Nephrol. 1996;16:402–8.
36. Hara I, Miyake H, Yamanaka K, Hara S, Arakawa S, Kamidono S. Expression of CD44 adhesion molecules in nonpapillary renal cell carcinoma and normal kidneys. Urology. 1999;54:562–6.
37. Rogers SA, Padanilam BJ, Hruska KA, Giachelli CM, Hammerman MR. Metanephric osteopontin regulates nephrogenesis in vitro. Am J Physiol. 1997;272:F469-76.
38. Wada J, Kumar A, Liu Z, Ruoslahti E, Reichardt L, Marvaldi J, et al. Cloning of mouse integrin alphaV cDNA and role of the alphaV-related matrix receptors in metanephric development. J Cell Biol. 1996;132:1161–76.
39. Ophascharoensuk V, Giachelli CM, Liaw L, Shankland SJ, Couser WG, Johnson RJ. Osteopontin (OPN) mediates early macrophage influx in renal interstitial inflammation: a study in OPN knockout (KO) mice. J Am Soc Nephrol. 1997;8:481A.
40. Shiraga H, Min W, VanDusen WJ, Clayman MD, Miner D, Terrell CH, et al. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA. 1992;89:426–30.
41. Worcester EM, Beshensky AM. Osteopontin inhibits nucleation of calcium oxalate crystals. Ann N Y Acad Sci. 1995;760:375–7.
42. Lieske JC, Leonard R, Toback FG. Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions. Am J Physiol. 1995;268:F604-2.
43. Asplin JR, Arsenault D, Parks JH, Coe FL, Hoyer JR. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int. 1998;53:194–9.
44. Lieske JC, Norris R, Toback FG. Adhesion of hydroxyapatite crystals to anionic sites on the surface of renal epithelial cells. Am J Physiol. 1997;273:F22433.
45. Hoyer JR, Otvos L Jr, Urge L. Osteopontin in urinary stone formation. Ann N Y Acad Sci. 1995;760:257–65.
46. Icer MA, Gezmen-Karadag M, Sozen S. Can urine osteopontin levels, which may be correlated with nutrition intake and body composition, be used as a new biomarker in the diagnosis of nephrolithiasis? Clin Biochem. 2018;60:38–43.
47. Liu CC, Huang SP, Tsai LY, Wu WJ, Juo SHH, Chou YH, et al. The impact of osteopontin promoter polymorphisms on the risk of calcium urolithiasis. Clin Chim Acta. 2010;411:739–43.
48. Yasui T, Fujita K, Hayashi Y, Ueda K, Kon S, Maeda M, et al. Quantification of osteopontin in the urine of healthy and stone-forming men. Urol Res. 1999;27:225–30.
49. Huang HS, Ma MC, Chen CF, Chen J. Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology. 2003;62:1123–8.
50. Gao B, Yasui T, Itoh Y, Li Z, Okada A, Tozawa K, et al. Association of osteopontin gene haplotypes with nephrolithiasis. Kidney Int. 2007;72:592–8.
51. Tsuji H, Tohru U, Hirotsugu U, Masanori I, Yuji H, Takashi K. Urinary concentration of osteopontin and association with urinary supersaturation and crystal formation. Int J Urol. 2007;14:630–4.
52. Yamate T, Kohri K, Umekawa T, Amasaki N, Amasaki N, Isikawa Y, et al. The effect of osteopontin on the adhesion of calcium oxalate crystals to Madin–Darby canine kidney cells. Eur Urol. 1996;30:388–93.
53. Yamate T, Kohri K, Umekawa T, Iguchi M, Kurita T. Osteopontin antisense oligonucleotide inhibits adhesion of calcium oxalate crystals in Madin–Darby canine kidney cell. J Urol. 1998;160:1506–12.
54. Yamate T, Kohri K, Umekawa T, Konya E, Ishikawa Y, Iguchi M, et al. Interaction between osteopontin on madin darby canine kidney cell membrane and calcium oxalate crystal. Urol Int. 1999;62:81–6.
55. Umekawa T, Kohri K, Kurita T, Hirota S, Nomura S, Kitamura Y. Expression of osteopontin messenger RNA in the rat kidney on experimental model of renal stone. Biochem Mol Biol Int. 1995;35:223–30.
56. Yagisawa T, Chandhoke PS, Fan J, Lucia S. Renal osteopontin expression in experimental urolithiasis. J Endourol. 1998;12:171–6.
57. Giachelli CM, Pichler R, Lombardi D, Denhardt DT, Alpers CE, Schwartz SM, et al. Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int. 1994;45:515–24.
58. Magil AB, Pichler RH, Johnson RJ. Osteopontin in chronic puromycin aminonucleoside nephrosis. J Am Soc Nephrol. 1997;8:1383–90.
59. Padanilam BJ, Martin DR, Hammerman MR. Insulin-like growth factor I-enhanced renal expression of osteopontin after acute ischemic injury in rats. Endocrinology. 1996;137:2133–40.
60. Nambi P, Gellai M, Wu HL, Prabhakar U. Upregulation of osteopontin in ischemia-induced renal failure in rats: a role for ET-1? Biochem Biophys Res Commun. 1997;241:212–4.
61. Persy VP, Verstrepen WA, Ysebaert DK, De Greef KE, De Broe ME. Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/reperfusion. Kidney Int. 1999;56:601–11.
62. Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int. 1995;47:1546–57.
63. Diamond JR, Kees-Folts D, Ricardo SD, Pruznak A, Eufemio M. Early and persistent up-regulated expression of renal cortical osteopontin in experimental hydronephrosis. Am J Pathol. 1995;146:1455–66.
64. Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S. Osteopontin expression in the kidney during unilateral ureteral obstruction. Miner Electrolyte Metab. 1998;24:227–37.
65. Young BA, Burdmann EA, Johnson RJ, Alpers CE, Giachelli CM, Eng E, et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int. 1995;48:439–48.
66. Pichler RH, Franceschini N, Young BA, Hugo C, Andoh TF, Burdmann EA, et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol. 1995;6:1186–96.
67. Eddy AA. Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. Kidney Int. 1996;50:1139–49.
68. Lan HY, Yu XQ, Yang N, Nikolic-Paterson DJ, Mu W, Pichler R, et al. De novo glomerular osteopontin expression in rat crescentic glomerulonephritis. Kidney Int. 1998;53:136–45.
69. Abbate M, Zoja C, Corna D, Capitanio M, Bertani T, Remuzzi G. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol. 1998;9:1213–24.
70. Yu XQ, Wu LL, Huang XR, Yang N, Gilbert RE, Cooper ME, et al. Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. Kidney Int. 2000;58:1469–80.
71. Wuthrich RP, Fan X, Ritthaler T, Sibalic V, Yu DJ, Loffing J, et al. Enhanced osteopontin expression and macrophage infiltration in MRL-Fas (lpr) mice with lupus nephritis. Autoimmunity. 1998;28:139–50.
72. Lerner SP, Linehan WM, Rathmell WK. Kidney cancer. Urol Oncol. 2012;30:948–51.
73. Funakoshi T, Lee CH, Hsieh JJ. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treat Rev. 2014;40:533–47.
74. Liu H, Chen A, Guo F, Yuan L. Influence of osteopontin short hairpin RNA on the proliferation and invasion of human renal cancer cells. J Huazhong Univ Sci Technol Med Sci. 2010;30:61–8.
75. Matusan K, Dordevic G, Stipic D, Mozetic V, Lucin K. Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol. 2006;94:325–31.
76. Rabjerg M, Bjerregaard H, Halekoh U, Jensen BL, Walter S, Marcussen N. Molecular characterization of clear cell renal cell carcinoma identifies CSNK2A1, SPP1 and DEFB1 as promising novel prognostic markers. APMIS. 2016;124:372–83.
77. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 2008;27:103–18.
78. Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal. 2009;3:311–22.
79. Magistroni R, D’Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 2015;88:974–89.
80. Sano N, Kitazawa K, Sugisaki T. Localization and roles of CD44, hyaluronic acid and osteopontin in IgA nephropathy. Nephron. 2001;89:416–21.
81. Wasilewska A, Taranta-Janusz K, Kuroczycka-Saniutycz E, Zoch-Zwierz W. Urinary OPN excretion in children with glomerular proteinuria. Adv Med Sci. 2011;56:193–9.
82. Thomas ME, Harris KP, Walls J, Furness PN, Brunskill NJ. Fatty acids exacerbate tubulointerstitial injury in protein-overload proteinuria. Am J Physiol Ren Physiol. 2002;283:F640-7.
83. Gang X, Ueki K, Kon S, Maeda M, Naruse T, Nojima Y. Reduced urinary excretion of intact osteopontin in patients with IgA nephropathy. Am J Kidney Dis. 2001;37:374–9.
84. Kaimori JY, Takenaka M, Nagasawa Y, Nakajima H, Izumi M, Akagi Y, et al. Quantitative analyses of osteopontin mRNA expression in human proximal tubules isolated from renal biopsy tissue sections of minimal change nephrotic syndrome and IgA glomerulonephropathy patients. Am J Kidney Dis. 2002;39:948–57.
85. Kitagori K, Yoshifuji H, Oku T, Sasaki C, Miyata H, Mori KP, et al. Cleaved form of osteopontin in urine as a clinical marker of lupus nephritis. PLoS One. 2016;11:e0167141.
86. Wenderfer SE, Gaut JP. Glomerular diseases in children. Adv Chronic Kidney Dis. 2017;24:364–71.
87. Bertelli R, Bonanni A, Caridi G, Canepa A, Ghiggeri GM. Molecular and cellular mechanisms for proteinuria in minimal change disease. Front Med (Lausanne). 2018;5:170.
88. Mezzano SA, Barría M, Droguett MA, Burgos ME, Ardiles LG, Flores C, et al. Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. Kidney Int. 2001;60:1366–77.
89. Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int. 2017;91:566–74.
90. Hoxha E, von Haxthausen F, Wiech T, Stahl RAK. Membranous nephropathy-one morphologic pattern with different diseases. Pflugers Arch. 2017;469:989–96.
91. Glassock RJ. Human idiopathic membranous nephropathy—a mystery solved? N Engl J Med. 2009;361:81–3.
92. Couser WG. Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol. 2012;23:381–99.
93. Mezzano SA, Droguett MA, Burgos ME, Ardiles LG, Aros CA, Caorsi I, et al. Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in human membranous nephropathy. Kidney Int. 2000;57:147–58.
94. Kotzin BL. Systemic lupus erythematosus. Cell. 1996;85:303–6.
95. Mills JA. Systemic lupus erythematosus. N Engl J Med. 1994;330:1871–9.
96. Giles BM, Boackle SA. Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus. Immunol Res. 2013;55:10–21.
97. Marks SD, Tullus K. Autoantibodies in systemic lupus erythematosus. Pediatr Nephrol. 2012;27:1855–68.
98. Ikeuchi H, Hiromura K, Kayakabe K, Tshilela KA, Uchiyama K, Hamatani H, et al. Renal outcomes in mixed proliferative and membranous lupus nephritis (class III/IV + V): a long-term observational study. Mod Rheumatol. 2016;26:908–13.
99. Kaleta B. Role of osteopontin in systemic lupus erythematosus. Arch Immunol Ther Exp. 2014;62:475–82.
100. Wong CK, Lit LC, Tam LS, Li EK, Lam CW. Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus. Rheumatology. 2005;44:602–6.
101. Ma R, Jiang W, Li Z, Sun Y, Wei Z. Intrarenal macrophage infiltration induced by T cells is associated with podocyte injury in lupus nephritis patients. Lupus. 2016;25:1577–86.
102. Salimi S, Noora M, Nabizadeh S, Rezaei M, Shahraki H, Milad MK, et al. Association of the osteopontin rs1126616 polymorphism and a higher serum osteopontin level with lupus nephritis. Biomed Rep. 2016;4:355–60.
103. Forton AC, Petri MA, Goldman D, Sullivan KE. An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus. Hum Mutat. 2002;19:459.
104. Xu AP, Liang YY, Lü J, Liang YY, Li JG, Lai DY, et al. Association of osteopontin gene polymorphism with lupus nephritis in Chinese Han population. Chin Med J (Engl). 2007;120:2124–8.
105. Lim AKH. Diabetic nephropathy–complications and treatment. Int J Nephrol Renovasc Dis. 2014;7:361–81.
106. Yamaguchi H, Igarashi M, Hirata A, Tsuchiya H, Sugiyama K, Morita Y, et al. Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J. 2004;51:499–504.
107. Yan X, Sano M, Lu L, Wang W, Zhang Q, Zhang R, et al. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2010;9:70.
108. Gordin D, Forsblom C, Panduru NM, Thomas MC, Bjerre M, Soro-Paavonen A, et al. Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2014;37:2593–600.
109. Talat MA, Sherief LM, El-Saadany HF, Rass AA, Saleh RM, Sakr MM. The role of osteopontin in the pathogenesis and complications of type 1 diabetes mellitus in children. J Clin Res Pediatr Endocrinol. 2016;8:399–404.
110. Cheema BS, Iyengar S, Ahluwalia TS, Kohli HS, Sharma R, Shah VN, et al. Association of an Osteopontin gene promoter polymorphism with susceptibility to diabetic nephropathy in Asian Indians. Clin Chim Acta. 2012;413:1600–4.
111. Nicholas SB, Liu J, Kim J, Ren Y, Collins AR, Nguyen L, et al. Critical role for osteopontin in diabetic nephropathy. Kidney Int. 2010;77:588–600.
112. Giacopelli F, Marciano R, Pistorio A, Catarsi P, Canini S, Karsenty G, et al. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genom. 2004;20:87–96.
113. Cheema BS, Iyengar S, Sharma R, Kohli HS, Bhansali A, Khullar M. Association between osteopontin promoter gene polymorphisms and haplotypes with risk of diabetic nephropathy. J Clin Med. 2015;4:1281–92.
114. Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, et al. Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) conference. Clin J Am Soc Nephrol. 2008;3:47–80.
115. Alchi B, Nishi S, Kondo D, Kaneko Y, Matsuki A, Imai N, et al. Osteopontin expression in acute renal allograft rejection. Kidney Int. 2005;67:886–96.
116. Rouschop KM, Roelofs JJ, Sylva M, Rowshani AT, Ten Berge IJ, Weening JJ, et al. Renal expression of CD44 correlates with acute renal allograft rejection. Kidney Int. 2006;70:1127–34.
117. Jin ZK, Tian PX, Wang XZ, Xue WJ, Ding XM, Zheng J, et al. Kidney injury molecule-1 and osteopontin: new markers for prediction of early kidney transplant rejection. Mol Immunol. 2013;54:457–64.